<DOC>
	<DOCNO>NCT00571493</DOCNO>
	<brief_summary>This Phase I/II trial design study toxicity Maximum Tolerated Dose VELCADE combination BEAM autologous hematopoietic stem cell transplantation obtain preliminary estimate response rate combination .</brief_summary>
	<brief_title>VELCADE®-BEAM Autologous Hematopoietic Stem Cell Transplantation Non-Hodgkin 's Lymphoma , Mantle Cell Lymphoma</brief_title>
	<detailed_description>Primary Objective : To evaluate phase I study toxicity MTD addition VELCADE™ ( bortezomib ) standard BEAM autologous transplant regimen . The phase II portion study determine preliminary estimate response rate . Secondary Objectives : To obtain preliminary estimate response rate regimen . To obtain preliminary estimate event-free overall survival use regimen . Enrolled subject receive Velcade combination BEAM Autologous Hematopoietic Stem Cell Transplantation ( AHSCT ) . Phase I treatment administer Velcade four dose cohort , addition BEAM AHSCT . Three patient accrue dose cohort enrollment start dose cohort . These subject evaluate establish maximum tolerate dose Velcade combination BEAM autologous peripheral blood stem cell transplantation . Once establish , maximum tolerate dose utilized treat additional 20 subject . Follow-Up : Data collect utilized obtain preliminary estimate response rate , event-free overall survival use regimen .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Persistent , relapse refractory indolent nonHodgkin 's lymphoma ( Follicular grade I , II , III ) , nonHodgkin 's lymphoma , composite lymphoma ≥ 50 % tumor show follicular histology , transform follicular , lymphoplasmacytic , marginal zone lymphoma , small Lymphocytic Lymphoma ( include Tcell subtypes ) , mantle cell lymphoma relapse , refractory , PR1 CR1 ( MCL CR1 ) . Age &gt; 19 year . Signed write informed consent . Expected survival duration &gt; six month . Karnofsky Performance Status &gt; 70 . Eligible patient must : Liver function &lt; 3x upper limit normal ( ULN ) unless due disease ; ANC &gt; 500 cells/mm3 Platelet Count &gt; 50 mm3 . Patients &gt; age 60 clinical sign heart disease must ejection fraction ≥ 45 % LVEF . Patients clinical sign pulmonary insufficiency must DLCO measure &gt; 50 % predict value . Able collect &gt; 1.2 X 106/kg CD34+ cell transplantation . No serious disease condition , opinion investigator , would compromise patient 's ability participate study . Female patient must pregnant lactating . Male female patient reproductive potential must follow accept birth control measure . Patients HIV seropositive Serum creatinine &gt; 2.5mg/dL calculated creatinine clearance ≤ 50ml/min Total bilirubin &gt; 3 time upper limit normal ( unless due Gilberts disease malignancy ) , ALT AST &gt; 4 time upper limit normal Active infection time transplant Myocardial infarction within 6 month prior enrollment New York Hospital Association ( NYHA ) Class III IV heart failure uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality Screening document investigator medically relevant . Patient hypersensitivity bortezomib , boron mannitol . Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>non-hodgkin 's lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>BEAM</keyword>
	<keyword>Velcade</keyword>
</DOC>